Payment overview · 2025
General Payments
$267.31
16 reported records · 11 companies
Healthcare provider profile · identity verified
Kellee D. Frogge, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CAMPBELLSVILLE, KY · NPI 1467434928
Verified facts
What the public records show
CMS Open Payments records show Kellee D. Frogge, M.D. received $267.31 in general payments during 2025 across 16 reported records.
ABBVIE INC. accounted for 18.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $49.34 | 18.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.90 | 18.3% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $34.21 | 12.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.11 | 10.9% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $18.25 | 6.8% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.29 | 5.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.05 | 5.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.02 | 5.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.40 | 5.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.96 | 5.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.78 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $267.31 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $34.21 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.97 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.97 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $29.11 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.03 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.03 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.31 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $18.25 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.93 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.05 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.05 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.96 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 83 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
78 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 635 | 122 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 424 | 53 |
| Gabapentin | Gabapentin | 382 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 376 | 81 |
| Atorvastatin Calcium | Atorvastatin Calcium | 327 | 67 |
| Omeprazole | Omeprazole | 288 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 261 | 54 |
| Lorazepam | Lorazepam | 256 | 41 |
| Methylprednisolone | Methylprednisolone | 244 | 182 |
| Simvastatin | Simvastatin | 224 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 221 | 47 |
| Sertraline Hcl | Sertraline Hcl | 216 | 50 |
| Lisinopril | Lisinopril | 213 | 46 |
| Valsartan | Valsartan | 211 | 50 |
| Tramadol Hcl | Tramadol Hcl | 205 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 194 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 184 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 184 | 33 |
| Meloxicam | Meloxicam | 172 | 36 |
| Montelukast Sodium | Montelukast Sodium | 169 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 163 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 160 | 32 |
| Clonazepam | Clonazepam | 148 | 20 |
| Trazodone Hcl | Trazodone Hcl | 145 | 33 |
| Memantine Hcl | Memantine Hcl | 144 | 24 |
| Metformin Hcl | Metformin Hcl | 141 | 34 |
| Potassium Chloride | Potassium Chloride | 135 | 28 |
| Famotidine | Famotidine | 130 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 128 | 28 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 128 | 26 |
| Carvedilol | Carvedilol | 119 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 116 | 37 |
| Baclofen | Baclofen | 113 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 113 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 111 | 26 |
| Losartan Potassium | Losartan Potassium | 110 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 105 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 104 | 32 |
| Furosemide | Furosemide | 102 | 23 |
| Januvia | Sitagliptin Phosphate | 98 | 14 |
| Alprazolam | Alprazolam | 96 | 11 |
| Cefdinir | Cefdinir | 96 | 67 |
| Azithromycin | Azithromycin | 94 | 77 |
| Diazepam | Diazepam | 87 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 28 |
| Ozempic | Semaglutide | 83 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 81 | 16 |
| Donepezil Hcl | Donepezil Hcl | 80 | 12 |
| Eliquis | Apixaban | 78 | 18 |
| Allopurinol | Allopurinol | 77 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 74 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 14 |
| Metformin Hcl Er | Metformin Hcl | 74 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 74 | 46 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 73 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 68 | suppressed |
| Xarelto | Rivaroxaban | 66 | 13 |
| Irbesartan | Irbesartan | 61 | 13 |
| Sucralfate | Sucralfate | 60 | 16 |
| Atenolol | Atenolol | 59 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 11 |
| Spironolactone | Spironolactone | 59 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 58 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 58 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 57 | 33 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 55 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 55 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | suppressed |
| Temazepam | Temazepam | 52 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 15 |
| Ezetimibe | Ezetimibe | 51 | 13 |
| Meclizine Hcl | Meclizine Hcl | 51 | 22 |
| Primidone | Primidone | 48 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 47 | suppressed |
| Acyclovir | Acyclovir | 46 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 45 | suppressed |
| Digoxin | Digoxin | 45 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 33 |
| Fluconazole | Fluconazole | 44 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 28 |
| Estradiol | Estradiol | 43 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 43 | suppressed |
| Armour Thyroid | Thyroid,pork | 42 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 41 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 15 |
| Fenofibrate | Fenofibrate | 39 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 39 | 11 |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Latanoprost | Latanoprost | 37 | suppressed |
| Linzess | Linaclotide | 37 | suppressed |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Pregabalin | Pregabalin | 37 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 37 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | suppressed |
| Lovastatin | Lovastatin | 34 | suppressed |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Prednisone | Prednisone | 31 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 30 | suppressed |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Eszopiclone | Eszopiclone | 28 | suppressed |
| Klor-Con M20 | Potassium Chloride | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 13 |
| Glimepiride | Glimepiride | 27 | suppressed |
| Sotalol | Sotalol Hcl | 27 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Methotrexate | Methotrexate Sodium | 24 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | 11 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 18 |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Carbamazepine Er | Carbamazepine | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 16 |
| Finasteride | Finasteride | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Propylthiouracil | Propylthiouracil | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 12 |
| Ulticare Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 12 |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Nystatin | Nystatin | 14 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Quviviq | Daridorexant Hcl | 12 | suppressed |
| Vienva | Levonorgestrel/Ethin.Estradiol | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $267.31 · 16 records | ABBVIE INC. | Auvelity, BREZTRI, EVENITY, FANAPT, JARDIANCE, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, TRINTELLIX, UBRELVY, VRAYLAR, Wegovy, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error